The UVB1 Vitamin D analogue inhibits colorectal carcinoma progression

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Vitamin D analogs exhibit anticancer properties but are limited by severe side effects like hypercalcemia.
• Developing safer vitamin D analogs with potent antineoplastic activity is crucial for cancer therapy.

Purpose of the Study:

• To investigate the efficacy of a novel Gemini vitamin D analogue, UVB1, in inhibiting human colorectal carcinoma progression.
• To evaluate the safety profile of UVB1, specifically its potential to cause hypercalcemia.

Main Methods:

• In silico analysis of UVB1's binding affinity to the vitamin D receptor (VDR).
• In vitro assays using HCT116 colorectal carcinoma cells to assess apoptosis, migration, and invasion.
• In vivo studies in animal models to evaluate tumor volume reduction and toxicity.

Main Results:

• UVB1 demonstrated significant antineoplastic effects, inducing apoptosis and reducing migration and invasion of HCT116 cells.
• In vivo, UVB1 reduced tumor volume without observable toxic effects or hypercalcemia.
• In silico analysis revealed UVB1 has a higher affinity for VDR than calcitriol, with VDR conformation influencing biological effects.

Conclusions:

• UVB1 effectively inhibits colorectal cancer progression through apoptosis induction and reduced cellular motility.
• UVB1 represents a promising chemotherapeutic agent for colorectal cancer due to its efficacy and favorable safety profile.
• The enhanced binding affinity and VDR interaction of UVB1 contribute to its therapeutic potential.